Pulmonary Critical Care Associates of Baltimore Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2002
NCT00122018
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2002

Timeline

NOW
  • Now

Alternative names

Linda F. Barr, M.D. | Pulmonary Critical Care Associates of Baltimore

Active Ingredients

Drugs in Phase 2 Trials (2)

acetylcysteine (mucomyst) (1 trial)

fenoldopam (corlopam) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 2)

Kidney Failure, Chronic (Phase 2)

Renal Insufficiency (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2